Increasing responses to checkpoint inhibitors by extracorporeal apheresis

ABSTRACT

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway.

BACKGROUND

There is an increasing prevalence of cancer in human and its significant contribution to mortality means there is a continuing need for new therapies. Elimination of the cancer, a reduction in its size, the disruption of its supporting vasculature, or reducing the number of cancer cells circulating in the blood or lymph systems are goals of current cancer therapies. Mechanistically, therapies for cancer are designed to combat tumors or cells metastasizing from tumors typically rely on a cytotoxic activity. That activity might be a cytotoxic effect an active agent has itself or it might be an effect employed indirectly by the active agent such as through the modulation of immune responses.

It is known that genetic and epigenetic changes occur in tissues as they transform to take on the phenotype of a cancer cell. Different steps in the malignant transformation process, including acquisition of the mutator phenotype, which is associated with loss of tumor suppressor activity, often results in the generation of neoantigens, which are subject to immune recognition.

Various attempts have been made to help the immune system to fight tumors. One early approach involved a general stimulation of the immune system through the administration of bacteria (live or killed) to elicit a general immune response which would also be directed against the tumor. Existing innate stimulators of immunity include BCG [1-10], lyophilized incubation mixture of group A Streptococcus pyogenes (OK-432) [11-26], CSF-470 [27, 28], as well as doses of chemotherapies that can selectively suppress Treg cells [29-39].

As far back as 1975 [40], it was known that administration of non-specific immune activators could induce local and in some cases systemic regression of cancer. For example, in one study, 6 patients with intradermal metastases of malignant melanoma were treated with intralesional BCG. Four patients showed a good response with regression of injected, and in some cases, uninjected lesions, whereas the other two developed metastatic visceral disease and died. Three of the six patients had complete regression of all lesions, and one exhibited complete regression of untreated lesions. All remain free of disease. The fourth patient had complete regression of injected and of some untreated lesions, but developed widespread dissemination and died. Three of four responders (i.e. those patients in whom treated lesions decreased in size by more than 50% for more than 1 month) showed a dramatic increase in lymphocyte stimulation to melanoma antigens. All responders (four out of four) had a marked increase to phytohemagglutinin (PHA), whereas non responders had no increase in lymphocyte stimulation either to melanoma antigens or PHA. These data suggested the other important point, which is that innate immune activation can lead to stimulation of antigen-specific T cell and B cell mediated immune responses. Recent approaches aimed at helping the immune system specifically to recognize tumor-specific antigens involve immunization with cancer-specific antigens, typically combined with an adjuvant (a substance which is known to cause or enhance an immune response) to the subject. Tumor specific antigens are well known and include the group of cancer testes antigens (CT antigens) or germ cell antigens that are reactivated in cancerous tissues. It is known that the usual lack of a powerful immune response to tumor associated antigens (TAAs) is due to a combination of factors. T cells have a key role in the immune response, which is mediated through antigen recognition by the T cell receptor (TCR), and they coordinate a balance between co-stimulatory and inhibitory signals known as immune checkpoints. These inhibitory signals function as natural suppressors of the immune system as an important mechanism for for maintenance of self-tolerance and to protect tissues from damage when the immune system is responding to pathogenic infection. However, disregulated immune suppression reduces what could otherwise be a helpful response by the body to avoid the development of tumors. Cytokines, other stimulatory molecules such as CpG (stimulating dendritic cells), Toll-like receptor ligands and other molecular adjuvants enhance the immune response. Co-stimulatory interactions involving T cells directly can be enhanced using agonistic antibodies to receptors including OX40, CD28, CD27 and CD137. Other immune system activating therapies include blocking and/or depleting inhibitory cells or molecules and include the use of antagonistic antibodies against what are known as immune checkpoints [41]. It is known that immune cells express proteins that are immune checkpoints that control and down-regulate the immune response. These are best defined in T lymphocytes and include PD-1, CTLA-4, TIM-3 and LAG3. Tumor cells express the ligands to these receptors. When T cells bind the ligand to these proteins on the tumor cells, the T cell is turned off and does not attempt to attack the tumor cell. Thus, checkpoint immune suppression is part of the complex strategy used by the tumor to evade the patient's immune system and is responsible for resistance to immunotherapy. Biopharmaceutical companies have successfully developed therapeutic checkpoint inhibitors that block the receptor/ligand interaction to promote the adaptive immune response to the tumor. Six checkpoint inhibitors are currently approved, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and ipilimumab for a wide variety of solid tumors including melanoma, lung, bladder, gastric cancers and others. T cells are central to the immune response to cancers and there is interest in the field in using tumor infiltrating lymphocytes (TILs) in the treatment and understanding of cancer. Through their T cell receptors (TCRs), T cells are reactive to specific antigens within a tumor. Tumor cells carry genetic mutations, many of which contribute directly or indirectly to malignancy. A mutation in an expressed sequence will typically result in a neoantigen, an antigen that is not known to the immune system and thus recognized as foreign and able to elicit an immune response. The importance of TIL is that they are associated with superior patient prognosis including in gastric cancer [42], breast cancer [43-46], melanoma [47], head and neck cancer [48], thus suggesting an active role of the immune system in contributing to cancer survival.

Unfortunately, despite the great advances in understanding of the immune-cancer interaction, and development of novel first in class drugs around this concept, many patients still do not respond to immunotherapies, and in some cases, those that respond suffer from relapse. The current invention teaches means of augmenting efficacy of immunotherapies specifically of checkpoint inhibitors, by removal of tumor derived and/or tumor microenvironment derived immunological blocking factors using extracorporeal means.

SUMMARY

Embodiments herein are directed to methods of enhancing the efficacy of an immune checkpoint inhibitor administered to a patient suffering from a tumor comprising: identifying a patient suffering from a tumor; administering an immunological checkpoint inhibitor to said patient to treat said tumor or ameliorate the effects of said tumor; extracorporeally removing immunological blocking factors that inhibit the effectiveness of said immunological checkpoint inhibitor in an amount sufficient to augment the efficacy of said immunological checkpoint inhibitor in either treating or ameliorating the effects of said tumor, wherein said extracorporeal removal is conducted at a time selected from the group consisting of: before, concurrently, and subsequent to the administration of said immunological checkpoint inhibitor.

More specifically, disclosed herein are methods wherein said efficacy of said checkpoint inhibitor is based on an endpoint selected from the group consisting of: a) tumor regression; b) tumor stabilization; c) reduction in tumor growth; d) inhibition of metastasis; e) stabilization of metastasis; f) reduction of metastatic growth; g) encapsulation of tumor and/or metastasis; h) augmentation of cytokines associated with tumor inhibition; i) decrease in cytokines associated with tumor progression; j) suppression of angiogenesis; k) augmentation of tumor infiltrating lymphocytes; l) switch of intratumoral macrophages from M2 to M1 phenotype; m) augmentation of tumor infiltrating dendritic cells; n) augmentation of tumor infiltrating killer T-cells o) reduction of tumor associated T regulatory cells; and p) reduction in tumor associated myeloid suppressor cells.

According to further embodiments, said checkpoint inhibitor is an agent capable of suppressing activity of a molecule selected from the group consisting of: PD-1, PD-L1, CTLA-4, PD-L2, LAG3, Tim3, 2B4, A2aR, ID02, B7413, B7-H4, BTLA, CD2, CD20, CD27, CD28, CD30, CD33, CD40, CD52, CD70, CD112, CD137, CD160, CD226, CD276, DR3, OX-40, GAL9, GITR, ICOS, HVEM, IDO1, KIR, LAIR, LIGHT, MARCO, PS, SLAM, TIGIT, VISTA, and VTCN1

According to other embodiments said immunological blocking factor is soluble TNF-alpha receptor.

According to further embodiments, disclosed herein are methods wherein said immunological blocking factor is selected from the group consisting of: a) soluble HLA-G; b) soluble MICA; c) interleukin-10; d) interleukin-20; e) VEGF; f) soluble IL-2 receptor; g) soluble IL-15 receptor; h) interleukin-35 and i) soluble interferon gamma receptor.

According to more specific embodiments, said removal of soluble TNF-alpha receptor is performed by affinity capture to TNF-alpha trimers.

According to further embodiments said checkpoint inhibitor is administered via a route selected from the group consisting of: intravenously, intramuscularly, parenterally, nasally, intratumorally, intraosseously, subcutaneously, sublingually, intrarectally, intrathecally, intraventricularly, orally, intraocularly, topically, or via inhalation, nanocell and/or nanobubble injection.

According to more specific embodiments, the immunological checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, and CTLA-4.

According to other embodiments, the inhibitor of PD-1 is an anti-PD-1 antibody selected from the group consisting of nivolumab and pembrolizumab.

Further embodiment are directed to methods wherein the inhibitor of PD-L1 is anti-PD-L1 antibody selected from the group consisting of: BMS-936559, durvalumab, atezolizumab, avelumab, MPDL3280A, MED14736, MSB0010718C, and MDX1105-01.

According to other embodiments, the inhibitor of CTLA-4 is an anti-CTLA-4 antibody selected from the group consisting of ipilimumab and tremelimumab.

According to certain embodiments, said removal of said soluble TNF-alpha receptor is performed using an extracorporeal affinity capture substrate comprising immobilized TNF-alpha molecules selected from the group consisting of: TNF-alpha trimers, native TNF-alpha molecules, and mutated forms of TNF-alpha, wherein said immobilized TNF-alpha molecules on the extracorporeal affinity capture substrate have at least one binding site capable of selectively binding to soluble TNF alpha receptor from a biological fluid.

Further methods include embodiments wherein said removal of immunological blocking factors is performed using an apheresis system utilizing centrifugal plasma separation.

Additional methods include embodiments, wherein said removal of immunological blocking factors is performed using an apheresis system utilizing membrane plasma separation.

Other aspects embody methods wherein enhancing efficacy of an immune checkpoint inhibitor is accomplished by performing one or more clinical procedures involving the removal of tumor derived blocking factors to prepare and/or condition the patient.

Still further embodiments include methods wherein said removal of soluble TNF-alpha receptor is performed by affinity capture to TNF-alpha trimers.

According to more specific embodiments said checkpoint inhibitor is administered intravenously, intramuscularly, parenterally, nasally, intratumorally, intraosseously, subcutaneously, sublingually, intrarectally, intrathecally, intraventricularly, orally, topically, or via inhalation, nanocell and/or nanobubble injection.

According to further embodiments said extracorporeal removal of immune blocking factors primes antigen presenting cells for enhanced ability to produce interleukin-12 subsequent to administration of a checkpoint inhibitor.

Further embodiments are directed to an immune checkpoint inhibitor for use in a method of treating a tumor in a patient, the method comprising: identifying a patient suffering from a tumor; administering an immunological checkpoint inhibitor to said patient to treat said tumor or ameliorate the effects of said tumor; and extracorporeally removing immunological blocking factors that inhibit the effectiveness of said immunological checkpoint inhibitor, wherein said extracorporeal removal is conducted at a time selected from the group consisting of: before, concurrently, and subsequent to the administration of said immunological checkpoint inhibitor. All methods disclosed herein can be used with said immune checkpoint inhibitors.

DESCRIPTION OF THE INVENTION

The invention discloses means of augmenting therapeutic ability of immunological checkpoint inhibitors by removal of immunological blocking factors through extracorporeal means. In one embodiment, the invention relates to the field of cancer therapy, specifically means of augmenting efficacy of cancer therapy. In particular, the invention provides methods of generating T cell populations capable of promoting the suppression of cancer, as well as directly killing the cancer. As used herein, the term “treatment” refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and may be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include preventing occurrence or recurrence of disease, alleviation of symptoms, and. diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, lowering the rate of disease progression, amelioration or palliation of the disease state, and inducing remission or improving prognosis.

The term “extracorporeal means” is defined as the use of an extracorporeal device or system through which blood or blood constituents obtained from a patient are passed through a device for the removal of the immune inhibitor(s) and wherein the blood or blood constituents that are depleted of immune inhibitor(s) are reinfused into the patient. The extracorporeal device is comprised of materials that selectively binds to and captures the specified inhibitor(s) to prevent them from being reinfused into the patient.

The term “affinity capture” means the selective binding of a specific substance or molecule by a chemical attraction.

The term “affinity capture substrate” means a material comprising an affinity capture molecule.

The term “antibody” includes therapeutic antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altrimomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, calumaxontab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemluzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, perntumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, sirntuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tocilizumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49 and 3F8. In some embodiments the invention teaches the combination use of extracorporeal removal of blocking factors as a means of augmenting therapeutic efficacy of the mentioned antibodies. In other embodiments the combination of antibodies, together with extracorporeal removal of blocking factors, is further combined with administration of checkpoint inhibitors. The invention is particularly of importance to therapeutic antibodies whose actions are mediated by antibody dependent cellular toxicity. The mentioned antibodies can be utilized individually or in combination. Furthermore administration of other immune modulators is envisioned within the scope of the invention. Immune modulators may be activators of innate immunity such as toll like receptor agonists. Other immune modulators stimulate adaptive immunity such as T and B cells. Furthermore, immune stimulation by be achieved by removal of immune suppressive cells utilizing approaches that deplete myeloid derived suppressor cells, Th3 cells, T regulatory cells, type 2 neutrophils, type 2 macrophages and eosinophils.

The terms “antigen-presenting cell (s)”, “APC” or “APCs” include both intact, whole cells as well as other molecules (all of allogeneic origin) which are capable of inducing the presentation of one or more antigens, preferably in association with class I MHC molecules, and all types of mononuclear cells which are capable of inducing an allogeneic immune response. Preferably whole viable cells are used as APCs. Examples of suitable APCs are, but not limited to, whole cells such as monocytes, macrophages, DCs, monocyte-derived DCs, macrophage-derived DCs. B cells and myeloid leukemia cells e. g. cell lines THP-1, U937, HL-60 or CEM-CM3. Myeloid leukemia cells are said to provide so called pre-monocytes. In some embodiments of the invention, tumor induced immaturity of antigen presenting cells is overcome by extracorporeal removal of tumor associated blocking factors. Said removal results in a predisposition of antigen presenting cells to mature in response to administration of checkpoint inhibitors.

The terms “cancer”, “neoplasm” and “tumor” are used interchangeably and in either the singular or plural form, as appearing in the present specification and claims, refer to cells that have undergone a malignant transformation that makes diem pathological to the host organism. Primary cancer cells (that is, cells obtained from near the site of malignant transformation) can he readily distinguished from non-cancerous cells by well-established techniques, particularly histological examination. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but also any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and in vitro cultures and cell lines derived from cancer cells. When referring to a type of cancer that normally manifests as a solid tumor, a “clinically detectable” tumor is one that is detectable on the basis of tumor mass; e. g. by such procedures as CAT scan, magnetic resonance imaging (MRI), X-ray, ultrasound or palpation. Non-limiting examples of tumors/cancers relevant for the present invention are carcinomas (e.g. breast cancer, prostate cancer, lung cancer, colorectal cancer, renal cancer, gastric cancer and pancreatic cancer), sarcomas (e.g. bone cancer and synovial cancer), neuro-endocrine tumors (e.g. glioblastoma, medulloblastoma and neuroblastoma), leukemias, lymphomas and squamous cell cancer (e.g. cervical cancer, vaginal cancer and oral cancer). Further, non-limiting examples of tumors/cancers relevant for the present invention are, glioma, fibroblastoma, neurosarcoma, uterine cancer, melanoma, testicular tumors, astrocytoma, ectopic hormone-producing tumor, ovarian cancer, bladder cancer, Wilm's tumor, vasoactive intestinal peptide secreting tumors, head and neck squamous cell cancer, esophageal cancer, or metastatic cancer. Prostate cancer and breast cancer are particularly preferred.

For the practice of the invention, the term “chemotherapy” is meant to encompass any non-proteinaceous (i.e, non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include reactive oxygen agents such as artimesinin and alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; cailystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyne antibiotics (e.g., calichemicin, especially calicheamicin gammaII and calicheamicin phiI1, see, e.g., Agnew, Chem. Intl. Ed. Engl, 33:183-186 (1994); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (Adramycin™) (including morpholine-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrroline-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as demopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replinisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriemylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiopeta; taxoids, e.g., paclitaxel (TAXOL®, Bristol Meyers Squibb Oncology, Princeton, N.J.) and docetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitroxantrone; vincristine; vinorelbine (NAVELBINE®); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoids such as retinoic acid; capecitabine; FOLFIRI (fluorouracil, leucovorin, and irinotecan) and pharmaceutically acceptable salts, acids or derivatives of any of the above. In some embodiments the efficacy of chemotherapy is augmented by utilization of extracorporeal removal of blocking factors. Furthermore, combination of the mentioned chemotherapies may be utilized together with checkpoint inhibitors. The invention is particularly relevant in situations where efficacy of chemotherapy is related to immunological activity.

The terms “extracorporeal system” and “extracorporeal removal” refer to one or methods for depleting concentrations of substances from whole blood and/or plasma, wherein said substances are immune suppressive. Methods for depleting substances from plasma can utilize systems that perform plasma separation using centrifugal force or separation via membrane, including but not limited to tangential flow systems and/or capillary means. in one embodiment, said extracorporeal means is a single-chain TNF-alpha based affinity column, termed the “LSV-02” device, which may be used in combination with the Terumo Optia apheresis system.

The term “myeloid suppressor cell” is equivalent to immature myeloid progenitor cells, myeloid derived suppressor cells, natural suppressor cells, or immature neutrophil/monocyte precursors.

The terms “vaccine”, “immunogen”, or immunogenic composition” are used herein to refer to a compound or composition that is capable of conferring a degree of specific immunity when administered to a human or animal subject. As used in this disclosure, a “cellular vaccine” or “cellular immunogen” refers to a composition comprising at least one cell population, which is optionally inactivated, as an active ingredient. The immunogens, and immunogenic compositions of this invention are active, which mean that they are capable of stimulating a specific immunological response (such as an anti-tumor antigen or anti-cancer cell response) mediated at least in part by the immune system of the host. The immunological response may comprise antibodies, immunoreactive cells (such as helper/inducer or cytotoxic cells), or any combination thereof, and is preferably directed towards an antigen that is present on a tumor towards which the treatment is directed. The response may be elicited or re-stimulated in a subject by administration of either single or multiple doses. A compound or composition is “immunogenic” if it is capable of either: a) generating an immune response against an antigen (such as a tumor antigen) in a naive individual; or b) reconstituting, boosting, or maintaining an immune response in an individual beyond what would occur if the compound or composition was not administered. A composition is immunogenic if it is capable of attaining either of these criteria when administered in single or multiple doses.

The term “T-cell response” means the specific proliferation and activation of effector functions induced by a peptide in vitro or in vivo. For MHC class 1 restricted cytotoxic T cells, effector functions may be lysis of peptide-pulsed, peptide-precursor pulsed or naturally peptide-presenting target cells, secretion of cytokines, preferably Interferon-gama, TNF-alpha, or IL-2 induced by peptide, secretion of effector molecules, preferably granzymes or perforins induced by peptide, or degranulation.

The term “peptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are preferably 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 10, 11, 12 amino acids or even longer, and in case of MHC class II peptides (e.g. elongated variants of the peptides of the invention) they can be as long as 15, 16, 17, 18, 19, 20 or 23 or more amino acids in length. Furthermore, the term “peptide” shall include salts of a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. Preferably, the salts are pharmaceutical acceptable salts of the peptides, such as, for example, the chloride or acetate (trifluoro-acetate) salts. It has to be noted that the salts of the peptides according to the present invention differ substantially from the peptides in their state(s) in vivo, as the peptides are not salts in vivo. The term “peptide” shall also include “oligopeptide”. The term “oligopeptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention, as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 15 amino acids in length.

The human in need thereof may be an individual who has or is suspected of having a cancer. In some of variations, the human is at risk of developing a cancer (e.g., a human who is genetically or otherwise predisposed to developing a cancer) and who has or has not been diagnosed with the cancer. As used herein, an “at risk” subject is a subject who is at risk of developing cancer (e.g., a hematologic malignancy). The subject may or may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein. An at-risk subject may have one or more so-called risk factors, which are measurable parameters that correlate with development of cancer, such as described herein. A subject having one or more of these risk factors has a higher probability of developing cancer than an individual without these risk factor(s). These risk factors may include, for example, age, sex, race, diet, history of previous disease, presence of precursor disease, genetic (e.g., hereditary) considerations, and environmental exposure. In some embodiments, a human at risk for cancer includes, for example, a human whose relatives have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers. Prior history of having cancer may also be a risk factor for instances of cancer recurrence. In some embodiments, provided herein is a method for treating a human who exhibits one or more symptoms associated with cancer (e.g., a hematologic malignancy). In some embodiments, the human is at an early stage of cancer. In other embodiments, the human is at an advanced stage of cancer.

Overall survival (OS) is defined as the time elapsed from start of treatment until death of any cause. Progression Free Survival (PFS) (RECIST 1.1) is calculated from start of treatment until disease progression or death. Objective response rate [CR (Complete Response) or PR (Partial Response) or SD (Stable Disease)] is defined as the percent of patients with best confirmed response CR or PR or SD, using CT or MRI, and determined by a central reader per RECIST 1.1, The response must be confirmed by a subsequent determination greater than or equal to 4 weeks apart, In some instances PET is used. The evaluations and measurements are performed at screening, then at 8-week intervals starting from first treatment until PD (Progressive Disease) or initiation of another or additional anti-tumor therapy, whichever occurs first. In addition, scans are performed at each long-term follow-up visit until progression.

In one embodiment of the invention patients are chosen in which a high degree of cancer associated immune suppression present. Immune suppression is assessed using different means known in the art and can include quantification of number of immune cells in circulation, quantification of activity of immune cells in circulation, quantification of the number of immune cells found intratumorally, quantification of activity of immune cells found intratumorally, quantification of the number of immune cells found peritumorally, and quantification of activity of immune cells found peritumorally. In some embodiments of the invention, quantification of immune cells comprises identification and assessment of activity of cells possessing tumor cytolytic and/or tumor inhibitory activity, such cells include natural killer cells (NK), gamma delta T cells, natural killer T cells (NKT), innate lymphoid cells, cytotoxic T lymphocytes (CTL), and helper T cells (Th). Activities of immune cells could be ability to stimulate other immune cells, killing activity, tumor-growth inhibitory activity, as well as suppression of angiogenesis. Other means of assessing suppression of immunity includes quantification of immune suppressive cells. For example, elevations in immature dendritic cells, Th2 cells, Th3 cells, myeloid suppressor cells, M2 macrophages, T regulatory cells, N2 neutrophils, and infiltration by mesenchymal stem cells possessing immune suppressive properties, are all measurements for selecting patients with immune suppression.

In some embodiments, extracorporeal removal of blocking factors is utilized to reduce the immune modulatory activity of myeloid suppressor cells as a means of inducing immunological activation. Myeloid suppressor cells are believed to be similar to the “natural suppressor” cells described by the Singhal group in the 1970s. Natural suppressor cells were found to be bone marrow derived cells possessing ability to antigen-nonspecifically suppress T cell proliferation after immune activation [49-55], and are upregulated by cancer and pregnancy [56-63]. These properties are similar to the currently described properties of myeloid derived suppressor cells [64].

In some embodiments of the invention, vitamin D3 is added to extracorporeal removal of blocking factors in order to augment differentiation and/or loss of immune suppressive ability of said myeloid derived suppressor cells. Utilization of vitamin D3 to reduce cancer associated immune suppression is described in this publication and incorporated by reference [65, 66].

The invention teaches that in patients with pre-existing immune suppression, removal of extracorporeal blocking factors may be used to increase efficacy of checkpoint inhibitor drugs. For the practice of the invention, various checkpoint inhibitors may be utilized together with extracorporeal removal of immunological blocking factors for enhanced therapeutic activity. Examples of such checkpoint inhibitors include: a) Inhibitors of Programmed Death 1 (PD-1, CD279), such as nivolumab (OPDIVOR™, BMS-936558, MDX1106, or MK-34775), and pembrolizumab (KEYTRUDA®, MK-3475, SCH-900475, lambrolizumab, CAS Reg. No. 1374853-91-4), as well as the PD-1 blocking agents described in U.S. Pat. Nos. 7,488,802, 7,943,743, 8,008,449, 8,168,757, 8,217,149, WO 03042402, WO 2008156712, WO 2010089411, WO 2010036959, WO 2011066342, WO 2011159877, WO 2011082400, and WO 2011161699; b) Inhibitors of Programmed Death—Ligand 1 (PD-L1, also known as B7-H1 and CD274), including antibodies such as BMS-936559, MPDL3280A), MEDI4736, MSB0010718C, and MDX1105-01); also including: atezolizumab, durvalumab and avelumab; c) Inhibitors of CTLA-4, such as ipilimumab (YERVOY®, MDX-010, BMS-734016, and MDX-101), tremelimumab, antibody clone BNI3 (Abeam), RNA inhibitors, including those described in WO 1999/032619, WO 2001/029058, U.S. 2003/0051263, U.S. 2003/0055020, U.S. 2003/0056235, U.S. 2004/265839, U.S. 2005/0100913, U.S. 2006/0024798, U.S. 2008/0050342, U.S. 2008/0081373, U.S. 2008/0248576, U.S. 2008/055443, U.S. Pat. Nos. 6,506,559, 7,282,564, 7,538,095 and 7,560,438 (each incorporated herein by reference); d) inhibitors of PD-L2 (B7-DC, CD273), such as AMP-224 (Amplimune, Inc.) and rHIgM12B7; and e) Inhibitors of checkpoint proteins, including: LAG3, such as IMP321; TIM3 (HAVCR2); 2B4; A2aR, ID02; B7H1; B7-H3 or B7H3, such as antibody MGA271; B7H4; BTLA; CD2; CD20, such as ibritumomab tiuxetan, ofatumumab, rituximab, obinutuzumab and tositumomab; CD27, such as CDX-1127; CD28; CD3O, such as brentuximab vedotin; CD33, such as gemtuzumab ozogamicin; CD40; CD52, such as alemtuzumab; CD70; CD80; CD86; CD112; CD137; CD160; CD226; CD276; DR3; OX-40 (TNFRSF.sub.4 and CD134); GAL9; GITR; such as TRX518; HAVCR2; HVEM; ID01; ICOS (inducible T cell costimulator; CD278); such as MEDI570 (Medimmune LLC) and AMG557 (Amgen); KIR; LAIR; LIGHT; MARCO (macrophage receptor with collageneous structure); PS (phosphatidylserine); SLAM; TIGIT; VISTA; and VTCNI; or a combinations thereof. In another variation, the checkpoint inhibitor is an inhibitor of a checkpoint protein selected from the group of PD-1, PD-L1 and CTLA-4. In another variation, the checkpoint inhibitor is selected from the group of an anti-PD-1 antibody, and anti-PD-L1 antibody and an anti-CTLA-4 antibody. In one variation, the anti-PD-1 antibody is selected from the group of nivolumab, pembrolizumab, and lambrolizumab. In another variation, the anti-PD-L1 antibody is selected from the group of as BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, and MDX1105-01. In yet other variations, the anti-PD-L1 antibody is selected from the group of durvalumab, atezolizumab, and avelumab, In another variation, the anti-CTLA-4 antibody is selected from the group of ipilimumab and tremelimumab. In one embodiment, the check point inhibitor is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, MDX1105-01, durvalumab, atezolizumab, avelumab, ipilimumab, and tremelimumab. In certain embodiment, the check point inhibitor is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, durvalumab, atezolizumab, avelumab, ipilimumab, and tremelimumab. In one embodiment, the check point inhibitor is selected from the group consisting of nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab. Said checkpoint inhibitors listed may be administered via multiple methods, including but not limited intravenously, intramuscularly, parenterally, nasally, intratumorally, intraosseously, subcutaneously, sublingually, intrarectally, intrathecally, intraventricularly, orally, intra-ocular, topically, or via inhalation, nanocell and/or nanobubble injection. For practices of the invention, the enhancement of efficacy of an immune checkpoint inhibitor may be accomplished by performing one or more clinical procedures involving the removal of tumor derived blocking factors to prepare and/or condition the patient. Said removal may be performed at various time points prior to administration of said checkpoint inhibitor(s). The determination of time points of removal, in some embodiments, is performed based on immunological and/or oncological assessment of the patient. In some situations, immune activity of the patient assessed, and used as a basis for determining the amount and frequency of extracorporeal treatments prior to administration of checkpoint inhibitors. In some situations, it may be desirable to continue extracorporeal treatments while administering checkpoint inhibitors, Furthermore, in some situations it may be desirable to continue extracorporeal treatment following administration of checkpoint inhibitors.

In some embodiments, checkpoint inhibitor drugs are increased in efficacy by removal of extracorporeal blocking factors. Said checkpoint inhibitor may be used to further increase in efficacy by addition of one or more cancer vaccines, which is referred to as “active immunization”. In some embodiments of the invention, administration of checkpoint inhibitors is performed together with active immunization. Immunization may take the form of peptides, proteins, altered peptide ligands, and cell therapy,

Antigens known to be found on cancer, and useful for the practice of the invention include: epidermal growth factor receptor (EGFR, EGFR1, ErbB-1, HER1); ErbB-2 (HER2/neu), ErbB-3/HER3, ErbB-4/HER4, EGFR ligand family; insulin-like growth factor receptor (IGFR) family, IGF-binding proteins (IGFBPs), IGFR ligand family (IGF-1R); platelet derived growth factor receptor (PDGFR) family, PDGFR ligand family; fibroblast growth factor receptor (FGFR) family, FGFR ligand family, vascular endothelial growth factor receptor (VEGFR) family, VEGF family; HGF receptor family; TRK receptor family; ephrin (EPH) receptor family; AXL receptor family; leukocyte tyrosine kinase (LTK) receptor family; TIE receptor family, angiopoietin 1, 2; receptor tyrosine kinase-like orphan receptor (ROR) receptor family; discoidin domain receptor (DDR) family; RET receptor family; KLG receptor family; RYK receptor family; MuSK receptor family; transforming growth factor alpha (TGF-alpha), TGF-alphareceptor; transforming growth factor-beta (TGF-beta), TGF-beta receptor; interleukin beta receptor alpha2 chain (IL13Ralpha2); interleukin-6 (IL-6), IL-6 receptor; interleukin-4. IL-4 receptor; cytokine receptors, Class I (hematopoietin family) and Class II (interferon/1L-10 family) receptors; tumor necrosis factor (TNF) family, TNF-alpha; tumor necrosis factor (TNF) receptor superfamily (TNTRSF); death receptor family, TRAIL-receptor; cancer-testis (CT) antigens; lineage-specific antigens; differentiation antigens; alpha-actinin-4; ARTC1, breakpoint cluster region—Abelson (Bcr-abl) fusion products; B-RAF; caspase-5 (GASP-5); caspase-8 (CASP-8); beta-catenin (CTNNB1); cell division cycle 27 (CDC27); cyclin-dependent kinase 4 (CDK4); CDKN2A; COA-1; dek-can fusion protein; EFTUD-2; Elongation factor 2 (ELF2); Ets variant gene 6/acute myeloid leukemia 1 gene EFS (ETC6-AML1) fusion protein; fibronectin (FN); GPNMB; low density lipid receptor/GDP-L fucose; beta-D-galactose 2-alpha-Lfucosyltraosferase (LDLR/FUT) fusion protein; HLA-A2; MLA-A11; heat shock protein 70-2 mutated (HSP70-2M); KIAA0205; MART2; melanoma ubiquitous mutated 1, 2, 3 (MUM-1, 2, 3); prostatic acid phosphatase (PAP); neo-PAP; Myosin class 1; NFYC; OGT, OS-9; pml-RARalpha fusion protein; PRDX5; PTPRK. K-ras (KRAS2); N-ras (NRAS); HRAS; RBAF600; SIRT12; SNRPD1; SYT-SSX1 or -SSX2 fusion protein; Triosephosphate Isomerase; BAGE; BAGE-1; BAGE-2, 3, 4, 5; GAGE-1, 2, 3, 4, 5, 6, 7, 8; GnT-V (aberrant N-acetyl glucosaminyl transferase V; MGAT5), HERV-K MEL, KK-LC, KM-I4N-1, LAGE, LAGE-1, CTL-recognized antigen on melanoma (CAMEL), MAGE-A1 (MAGE-1); MAGE-A2; MAGE-A3; MAGE-A4; MAGE-A5; MAGE-A6; MAGE-A8; MAGE-A9; MAGE-A10; MAGE-A11; MAGE-A12; MAGE-3; MAGE-B1; MAGE-B2; MAGE-B5; MAGE-B6; MAGE-C1; MAGE-C2; mucin 1 (MUC1); MART-1/Melan-A (MLANA); gp100; gp100/Pme117 (SILV); tyrosinase (TYR); TRP-1; HAGE; NA-88; NY-ESO-1; NY-ESO-1/LAGE-2; SAGE, Sp17; SSX-1, 2, 3, 4; TRP2-1NT2; carcino-embryonic antigen (CEA); Kallikrein 4; mammaglobin-A; OA1; prostate specific antigen (PSA); prostate specific membrane antigen; TRP-1/, 75; TRP-2 adipophilin; interferon inducible protein absent in melanoma 2 (AIM-2); BING-4; CPSF; cyclin D1; epithelial cell adhesion molecule (Ep-CAM); EpbA3; fibroblast growth factor-5 (FGF-5); glycoprotein 250 (gp250 intestinal carboxyl esterase (iCE); alpha-feto protein (AFP); M-CSF; mdm-2; MUCI; p53 (TP53); PBF; PRAME; PSMA; RAGE-1; RNF43; RU2AS; SOX10; STEAP1; survivin (BIRCS); human telomerase reverse transcriptase (hTERT); telomerase; Wilms' tumor gene (WT1); SYCP1; BRDT; SPANX; XAGE; ADAM2; PAGE-5; LIP1; CTAGE-1; CSAGE; MMA1; CAGE; BORIS; HOM-TES-85; AF15q14; HCA661; LDHC; MORC; SGY-1; SPO11; TPX1; NY-SAR-35; FTHL17; NXF2 TDRD1; TEX 15; FATE; TPTE; immunoglobulin idiotypes; Bence-Jones protein; estrogen receptors (ER); androgen receptors (AR); CD40; CD30; CD20; CD19; CD33; CD4; CD25; CD3; cancer antigen 72-4 (CA 72-4); cancer antigen 15-3 (CA 15-3); cancer antigen 27-29 (CA 27-29); cancer antigen 125 (CA 125); cancer antigen 19-9 (CA 19-9); beta-human chorionic gonadotropin; 1-2 microglobulin; squamous cell carcinoma antigen; neuron-specific enolase; heat shock protein gp96; GM2, sargramostim; CTLA-4; 707 alanine proline (707-AP); adenocarcinoma antigen recognized by T cells 4 (ART-4); carcinoembryogenic antigen peptide-1 (CAP-1); calcium-activated chloride channel-2 (CLCA2); cyclophilin B (Cyp-B); and human signet ring tumor-2 (HST-2).

In one embodiment, the invention teaches the use of removal of extracorporeal blocking factors to increase the number of dendritic cells infiltrating tumors. The utilization of dendritic cells as an immunotherapy is known in the art and ways of using dendritic cell therapy are defined in the following examples for melanoma [67-118], soft tissue sarcoma [119], thyroid [120-122], glioma [123-144], multiple myeloma ,[145-153], lymphoma [154-156], leukemia [157-164], as well as liver [165-170], lung [171-184], ovarian [185-188], and pancreatic cancer [189-191]. In other embodiments the invention teaches the use of extracorporeal removal of immunological blocking factors for augmentation of existing dendritic cells to infiltrate tumors. Means of assessing dendritic cell infiltration are known in the art and described in the following examples: for gastric cancer [192-195], head and neck cancer [196-200], cervical cancer [201], breast cancer [202-204], lung cancer [205], colorectal cancer [206-208], liver cancer [209, 210], gall bladder cancer [211, 212], and pancreatic cancer [213].

REFERENCES

-   -   1. Mukherjee, N., K. M. Wheeler, and R. S. Svatck, Bacillus         Calmette-Guerin treatment of bladder cancer: a systematic review         and commentary on recent publications. Curr Opin Urol, 2019.     -   2. Lemdani, K., et al., Local immunomodulation combined to         radiofrequency ablation results in a complete cure of local and         distant colorectal carcinoma. Oncoimmunology, 2019. 8 (3): p.         1550342.     -   3. Pettenati, C. and M. A. Ingersoll, Mechanisms of BCG         immunotherapy and its outlook for bladder cancer. Nat Rev         Urol, 2018. 15 (10): p. 615-625.     -   4. Mukherjee, N. and R. Svatck, Cancer Immune Therapy:         Prognostic Significance and Implications for Therapy of PD-1 in         BCG-Relapsing Bladder Cancer. Ann Surg Oncol, 2018. 25 (9): p.         2498-2499.     -   5. Godoy-Calderon, M. J., et al., Autologous tumor         cells/bacillus Calmette-Guerin/formalin-based novel breast         cancer vaccine induces an immune antitumor response.         Oncotarget, 2018. 9 (29): p. 20222-20238.     -   6. Davis, R. L., 3rd, W. Le, and Z. Cui, Granulocytes as an         effector mechanism of BCG therapy for bladder cancer. Med         Hypotheses, 2017. 104: p. 166-169.     -   7. Morales, A., BCG: A throwback from the stone age of vaccines         opened the path for bladder cancer immunotherapy. Can J         Urol, 2017. 24 (3): p. 8788-8793.     -   8. Kowalewicz-Kulbat, M. and C. Locht, BCG and protection         against inflammatory and auto-immune diseases. Expert Rev         Vaccines, 2017. 16 (7): p. 1-10.     -   9. Prack Mc Cormick, B., et al., Bacillus Calmette-Guerin         improves local and systemic response to radiotherapy in invasive         bladder cancer. Nitric Oxide, 2017. 64: p. 22-30.     -   10. Pichler, R., et al., Tumor-infiltrating immune cell         subpopulations influence the oncologic outcome after         intravesical Bacillus Calmette-Guerin therapy in bladder cancer.         Oncotarget, 2016. 7 (26): p. 39916-39930.     -   11. Pan, K., et al., OK-432 synergizes with IFN-gamma to confer         dendritic cells with enhanced antitumor immunity. Immunol Cell         Biol, 2014. 92 (3): p. 263-74.     -   12. Ohe, O., et al., Effect of soluble factors derived from oral         cancer cells on the production of interferon-gamma from         peripheral blood mononuclear cells following stimulation with         OK-432. Oncol Rep, 2013. 30 (2): p. 945-51.     -   13. Hirayama, M., et al., Overcoming regulatory T-cell         suppression by a lyophilized preparation of Streptococcus         pyogenes. Eur J Immunol, 2013. 43 (4): p. 989-1000.     -   14. Chen, I. J., et al., Vaccination with OK-432 followed by         TC-1 tumor lysate leads to significant antitumor effects. Reprod         Sci, 2011. 18 (7): p. 687-94.     -   15. Oshikawa, T., et al., Antitumor effect of OK-432-derived         DNA: one of the active constituents of OK-432, a streptococcal         immunotherapeutic agent. J Immunother, 2006. 29 (2): p. 143-50.     -   16. Okamoto, M., et al., Mechanism of anticancer host response         induced by OK-432, a streptococcal preparation, mediated by         phagocytosis and Toll-like receptor 4 signaling. J         Immunother, 2006. 29 (1): p. 78-86.     -   17. Kimura, T., et al., Final report of a randomized controlled         study with streptococcal prep OK-432 as a supplementary         immunopotentiator for laryngeal cancer. Acta Otolaryngol         Suppl, 1996. 525: p. 135-41.     -   18. Ozaki, S., et al., Mechanism pf tumoricidal activity of         OK-432-specific L3T4+Lyt2− T-cells. Cancer Res, 1990. 50         (15): p. 4630-4.     -   19. Abe, Y., et al., The endogenous induction of tumor necrosis         factor serum (TNS) for the adjuvant postoperative immunotherapy         of cancer—changes in immunological markers of the blood. Jpn J         Surg, 1990. 20 (1): p. 19-26.     -   20. Nio, Y., et al., Cytotoxic and cytostatic effects of the         streptococcal preparation OK-432 and its subcellular fractions         on human ovarian tumor cells. Cancer, 1989. 64 (2): p. 434-41.     -   21. Hanaue, H., et al,, Hemolytic streptococcus preparation         OK-432; beneficial adjuvant therapy in recurrent gastric         carcinoma. Tokai J Exp Med, 1987. 12 (4): p. 209-14.     -   22. Ujiie, T., OK-432-mediated augmentation of antitumor         immunity and generation of cytotoxic T lymphocytes. Jpn J Exp         Med, 1987. 57 (2): p. 103-15.     -   23. Bonavida, B., J. Katz, and T. Hoshino, Mechanism of NK         activation by OK-432 (Streptococcus pyogenes). I. Spontaneous         release of NKCF and augmentation of NKCF production following         stimulation with NK target cells. Cell Immunol, 1986. 102         (1): p. 126-35.     -   24. Uchida, A., Augmentation of autologous tumor killing         activity of tumor-associated large granular lymphocytes by the         streptococcal preparation OK432. Methods Find Exp Clin         Pharmacol, 1986. 8 (2): p. 81-4.     -   25. Toge, T., et al., Effects of intraperitoneal administration         of OK-432 for patients with advanced cancer. Jpn J Surg, 1985.         15 (4): p. 260-5.     -   26. Sakai, S., et al., Studies on the properties of a         streptococcal preparation OK-432 (NSC-B116209) as an         immunopotentiator. I. Activation of serum complement components         and peritoneal exudate cells by group A streptococcus. Jpn J Exp         Med, 1976. 46 (2): p. 123-33.     -   27. Pampena, M. B., et al., Dissecting the Immune Stimulation         Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma         Patients: Long Term Antitumor Immunity and Short Term Release of         Acute Inflammatory Reactants. Front Immunol, 2018. 9: p. 2531.     -   28. Pampena, M. B., et al., Early Events of the Reaction         Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro         Analysis of Immune Recruitment and Cytokine Release. Front         Immunol, 2017, 8: p. 1342.     -   29. Lusiak, M. E., et al., Inhibition of CD4(+)25+ T regulatory         cell function implicated in enhanced immune response by low-dose         cyclophosphamide. Blood, 2005. 105 (7): p. 2862-8.     -   30. Beyer, M., et al., Reduced frequencies and suppressive         junction of CD4+CD25hi regulatory T cells in patients with         chronic lymphocytic leukemia after therapy with fludarabine.         Blood, 2005. 106 (6): p. 2018-25.     -   31. Brode, S., et al., Cyclophosphamide-induced type-1 diabetes         in the NOD mouse is associated with a reduction of         CD4+CD25+Foxp3+ regulatory T cells. J Immunol, 2006. 177         (10): p. 6603-12.     -   32. Salem, M. L., et al., Defining the ability of         cyclophosphamide preconditioning to enhance the antigen-specific         CD8+ T-cell response to peptide vaccination: creation of a         beneficial host microenvironment involving type I IFNs and         myeloid cells. J Immunother, 2007. 30 (1): p. 40-53.     -   33. Liu J. Y., et al., Single administration of low dose         cyclophosphamide augments the antitumor efect of dendritic cell         vaccine. Cancer Immunol Immunother, 2007. 56 (10): p. 1597-604.     -   34. van der Most, R. G., et al., Tumor eradication after         cyclophosphamide depends on concurrent depletion of regulatory T         cells: a role for cycling TNFR2-expressing effector-suppressor T         cells in limiting effective chemotherapy. Cancer Immunol         Immunother, 2009. 58 (8): p. 1219-28.     -   35. Greten, T. F., et al., Low-dose cyclophosphamide treatment         impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell         responses in patients with advanced HCC. J Immunother, 2010. 3         3(2): p. 211-8.     -   36. Zhao, J., et al., Selective depletion of CD4+CD25+Foxp3+         regulatory T cells by low-dose cyclophosphamide is explained by         reduced intracellular ATP levels. Cancer Res, 2010. 70 (12): p.         4850-8.     -   37. Vermeij, R., et al., Potentiation of a p53-SLP vaccine by         cyclophosphamide in ovarian cancer: a single-arm phase II study.         Int J Cancer, 2012. 131 (5): p. E670-80.     -   38. Xia, Q., et al., Cyclophosphamide enhances anti-tumor         effects of a fibroblast activation protein alpha-based DNA         vaccine in tumor-bearing mice with murine breast carcinoma.         Immunopharmacol Immunotoxicol, 2017. 39 (1): p. 37-44.     -   39. Noordam, L., et al., Low-dose cyclophosphamide depletes         circulating naive and activated regulatory T cells in malignant         pleural mesothelioma patients synergistically treated with         dendritic cell-based immunotherapy. Oncoimmunology, 2018. 7         (12): p. e474318.     -   40. Lieberman, R., J. Wybran, and W. Epstein, The immunologic         and histopathologic changes of BCG-mediated tumor regression in         patients with malignant melanoma. Cancer, 1975. 35 (3): p.         756-77.     -   41. Leach, D. R., M. F. Krummel, and J. P. Allison, Enhancement         of antitumor immunity by CTLA-4 blockade. Science, 1996. 271         (5256): p. 1734-6.     -   42. Zhang, D., et al., Scoring System for Tumor-Infiltrating         Lymphocytes and Its Prognostic Value for Gastric Cancer. Front         Immunol, 2019. 10: p. 71.     -   43. Huang, J., et al., Changes of Tumor Infiltrating Lymphocytes         after Core Needle Biopsy and the Prognostic Implications in         Early Stage Breast Cancer: A Retrospective Study. Cancer Res         Treat, 2019.     -   44. Mivoshi, Y., et al., Associations in tumor infiltrating         lymphocytes between clinicopathological factors and clinical         outcomes in estrogen receptor-positive/human epidermal growth         factor receptor type 2 negative breast cancer. Oncol Lett, 2019.         17 (2): p. 2177-2186.     -   45. Loi, S., et al., Tumor-Infiltrating Lymphocytes and         Prognosis: A Pooled Individual Patient Analysis of Early Stage         Triple-Negative Breast Cancers. J Clin Oncol, 2019. 37 (7): p.         559-569.     -   46. Sonderstrup, I. M. H., et al., Evaluation of         tumor-infiltrating lymphocytes and association with prognosis in         BRCA-mutated breast cancer. Acta Oncol, 2019: p. 1-8.     -   47. Wong, P. F., et al., Multiplex Quantitative Analysis of         Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in         Metastatic Melanoma. Clin Cancer Res, 2019.     -   48. Shimizu, S., et al., Tumor-infiltrating CD8(+) T-cell         density is an independent prognostic marker for oral squamous         cell carcinoma. Cancer Med, 2019. 8 (1): p. 80-93.     -   49. Bennett, J. A., V. S. Rao, and M. S. Mitchell, Systemic         bacillus Calmette-Guerin (BCG) activates natural suppressor         cells. Proc Natl Acad Sci USA, 1978. 75 (10): p. 5142-4.     -   50. Bennett, J. A. and J. C. Marsh, Relationship of Bacillus         Calmette-Guerin induced suppressor cells to hematopoietic         precursor cells. Cancer Res, 1980. 40 (1): p. 80-5.     -   51. Strober, S., Natural suppressor (NS) cells, neonatal         tolerance, and total lymphoid irradiation: exploring obscure         relationships. Annu Rev Immunol, 1984. 2: p. 219-37.     -   52. Schwadron, R. B., D M. Gandour, and S. Strober, Cloned         natural suppressor cell lines derived from the spleens of         neonatal mice. J Exp Med, 1985. 162 (1): p. 297-310.     -   53. Noga, S. J., et al., Characterization of the natural         suppressor cell population in adult rat bone marrow. J Leukoc         Biol, 1988. 43 (3): p. 279-87.     -   54. Sugiura, K., et al., Enrichment of neutral suppressor         activity in a wheat germ agglutinin positive hematopoietic         progenitor-enriched fraction of monkey bone marrow. Blood, 1990.         75 (5): p. 1125-31.     -   55. Sugiura, K., et al., Enrichment of murine bone marrow         natural suppressor activity in the fraction of hematopoietic         progenitors with interleukin 3 receptor-associated antigen. Exp         Hematol, 1992. 20 (2): p. 256-63.     -   56. Clark, D. A., et al., Decidua-associated suppressor cells in         abortion-prone DBA/2-mated CBA/J mice that release bioactive         transforming growth factor beta2-related immunosuppressive         molecules express a bone marrow-derived natural suppressor cell         marker and gamma delta T-cell receptor. Biol Reprod, 1997. 56         (5): p. 1351-60.     -   57. Gronvik, K. O., D. W. Hoskin, and R. A. Murgita, Monoclonal         antibodies against murine neonatal and pregnancy-associated         natural suppressor cells induce resorption of the fetus. Scand J         Immunol, 1987. 25 (5): p. 533-40.     -   58. Subiza, J. L., et al., Development of splenic natural         suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J         Cancer, 1989. 44 (2): p. 307-14.     -   59. Vinuela, J. E., et al., Antigen shedding vs. development of         natural suppressor cells as mechanism of tumor escape in mice         hearing Ehrlich tumor. Int J Cancer, 1991. 47 (1): p. 86-91.     -   60. Hayamizu, K., et al., Induction of natural suppressor-like         cells from human adult peripheral blood lymphocytes by a         K562-derived factor. Transplantation, 1993. 55 (6): p. 1403-8.     -   61. Prechel, M. M., et al., Immune modulation by interleukin-12         in tumor-bearing mice receiving vitamin D3 treatments to block         induction of immunosuppressive granulocyte/macrophage progenitor         cells. Cancer Immunol Immunother, 1996. 42 (4); p. 213-20.     -   62. Young, M. R., et al., Increased recurrence and metastasis in         patients whose primery head and neck squamous cell carcinomas         secreted granulocyte-macrophage colony-stimulating factor and         contained CD34+ natural suppressor cells. Int J Cancer, 1997. 74         (1): p. 69-74.     -   63. Wright, M. A., et al., Stimulation of immune suppressive         CD34+ cells from normal bone marrow by Lewis lung carcinoma         tumors. Cancer Immunol Immunother, 1998. 46 (5): p. 253-60.     -   64. Martino, A., et al., Mycobacterium bovis bacillus         Calmette-Guerin vaccination mobilizes innate myeloid-derived         suppressor cells restraining in vivo T cell priming via         IL-IR-dependent nitric oxide production. J Immunol, 2010. 184         (4): p. 2038-47.     -   65. Wiers, K., et al., Failure of tumor-reactive lymph node         cells to kill tumor in the presence of immune-suppressive CD34+         cells can be overcome with vitamin D3 treatment to diminish         CD34+ cell levels. Clin Exp Metastasis, 1998. 16 (3): p. 275-82.     -   66. Wiers, K. M., et al., Vitamin D3 treatment to diminish the         levels of immune suppressive CD34+ cells increases the         effectiveness of adoptive immunotherapy. J Immunother, 2000. 23         (1): p. 115-24.     -   67. Nestle, P. O., et al., Vaccination of melanoma petients with         peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998.         4 (3): p. 328-32.     -   68. Chakraborty, N. G., et al., Immunization with a         tumor-cell-lysate-loaded         autologous-antigen-presenting-cell-based vaccine in melanoma.         Cancer Immunol Immunother, 1998. 47 (1): p. 58-64.     -   69. Wang, F., et al., Phase I trial of a MART-1 peptide vaccine         with incomplete Freund's adjuvant for resected high-risk         melanoma. Clin Cancer Res, 1999. 5 (10): p. 2756-65.     -   70. Thumer, B., et al., Vaccination with mage-3AI peptide-pulsed         mature, monocyte-derived dendritic cells expands specific         cytotoxic T cells and induces regression of some metastases in         advanced stage IV melanoma. J Exp Med, 1999. 190 (11): p.         1669-78.     -   71. Thomas, R., et al., Immature human monocyte-derived         dendritic cells migrate rapidly to draining lymph nodes after         intradermal injection for melanoma immunotherapy. Melanoma         Res, 1999. 9 (5): p. 474-81.     -   72. Mackensen, A., et al., Phase I study in melanoma patients of         a vaccine with peptide-pulsed dendritic cells generated in vitro         from CD34(+) hematopoietic progenitor cells. Int J Cancer, 2000.         86 (3): p. 385-92.     -   73. Panelli, M. C., et al., Phase I study in patients with         metastatic melanoma of immunization with dendritic cells         presenting epitopes derived from the melanoma-associated         antigens MART-1 and gp100. J Immunother, 2000. 23,(4): p.         487-98.     -   74. Schuler-Thumer, B., et al., Mage-3 and influenza-matrix         peptide-specific cytotoxic T cells are inducible in terminal         stage HLA-A2.1+ melanoma patients by mature monocyte-derived         dendritic cells. J Immunol, 2000. 165 (6): p. 3492-6.     -   75. Lau, R., et al., Phase I trial of intravenous peptide-pulsed         dendritic cells in patients with metastatic melanoma. J         Immunother, 2001. 24 (1): p. 66-78.     -   76. Banchereau, J., et al., Immune and clinical responses in         patients with metastatic melanoma to CD34(+) progenitor-derived         dendritic cell vaccine. Cancer Res, 2001. 61 (17): p. 6451-8.     -   77. Schuler-Thumer, B., et al., Rapid induction of         tumor-specific type 1 T helper cells in metastatic melanoma         patients by vaccination with mature, cryopreserved,         peptide-loaded monocyte-derived dendritic cells. J Exp         Med, 2002. 195 (10): p. 1279-88.     -   78. Palucka, A. K., et al., Single injection of CD34+         progenitor-derived dendritic cell vaccine can lead to induction         of T-cell immunity in patients with stage IV melanoma. J         Immunother, 2003. 26 (5): p. 432-9.     -   79. Bedrosian, I., et al., Intranodal administration of         peptide-pulsed mature dendritic cell vaccines results in         superior CD8+ T-cell function in melanoma patients. J Clin         Oncol, 2003. 21 (20): p. 3826-35.     -   80. Slingluff, C. L., Jr., et al., Clinical and immunologic         results of a randomized phase II trial of vaccination using four         melanoma peptides either administered in granulocyte-macrophage         colony stimulating factor in adjuvant or pulsed on dendritic         cells. J Clin Oncol, 2003. 21 (21): p. 4016-26.     -   81. Hersey, P., et al., Phase I/II study of treatment with         dendritic cell vaccines in patients with disseminated melanoma.         Cancer Immunol Immunother, 2004. 53 (2): p. 125-34.     -   82. Vilella, R., et al., Pilot study of treatment of         biochemotherapy-refractory stage IV melanoma patients with         autologous dendritic cells pulsed with a heterologous melanoma         cell line lysate. Cancer Immunol Immunother, 2004. 53 (7): p.         651-8.     -   83. Palucka, A. K., et al., Spontaneous proliferation and type 2         cytokine secretion by CD4+ T cells in patients with metastatic         melanoma vaccinated with antigen-pulsed dendritic cells. J Clin         Immunol, 2005. 25 (3): p. 288 95.     -   84. Bancherceu, J., et al., Immune and clinical outcomes in         patients with stage IV melanoma vaccinated with peptide-pulsed         dendritic cells derived from CD34+ progenitors and activated         with type 1 interferon. J Immunother, 2005. 28 (51: p. 505-16.     -   85. Trakatelli, M., et al., A new dendritic cell vaccine         generated with interleukin-3 and interferon-beta induces CD8+ T         cell responses against NA17-A2 tumor peptide in melanoma         patients. Cancer Immunol Immunother, 2006. 55 (4): p. 469-74.     -   86. Salcedo, M., et al., Vaccination of melanoma patients using         dendritic cells landed with an allogeneic tumor cell lysate.         Cancer Immunol Immunother, 2006. 55 (7): p. 819-29.     -   87. Linette, G. P., et al., Immunization using autologous         dendritic cells pulsed with the melanoma-associated antigen         gp100-derived G280-9V peptide elicits CD8+immunity. Clin Cancer         Res, 2005. 11 (21): p. 7692-9.     -   88. Escobar, A., et al., Dendritic cell immunizations alone or         combined with low doses of interleukin-2 induce specific immune         responses in melanoma patients. Clin Exp Immunol, 2005. 142         (3): p. 555-68.     -   89. Tuettenberg, A., et al., Induction of strong and persistent         MelanA/MART-1-specific immune responses by adjuvant dendritic         cell based vaccination of stage II melanoma patients. Int J         Cancer, 2006. 118 (10): p. 2617-27.     -   90. Schadendorf, D., et al., Dacarbazine (DTIC) versus         vaccination with autologous peptide-pulsed dendritic cells (DC)         in first-line treatment of patients with metastatic melanoma: a         randomized phase III trial of the DC study group of the DeCOG.         Ann Oncol, 2006. 17 (4): p. 563-70.     -   91. Di Pucchio, T., et al., Immunization of stage IV melanoma         patients with MelanA/MART-1 and gp100 peptides plus IFN-alpha         results in the activation of specific CD8(+) T cells and         monocyte/dendritic cell precursors. Cancer Res, 2006. 66 (9): p.         4943-51.     -   92. Nakai, N., et al., Vaccination of Japanese patients with         advanced melanoma with peptide, tumor lysate or both peptide and         tumor lysate-pulsed mature, monocyte-derived dendritic cells. J         Dermatol, 2006. 33 (7): p. 462-72.     -   93. Palucka, A. K., et al., Dendritic cells loaded with killed         allogeneic melanoma cells can induce objective clinical         responses and MART-1 specific CDS+ T-cell immunity. J         Immunother, 2006. 29 (5): p. 545-57.     -   94. Lesimple, T., et al., Immunologic and clinical effects of         injecting mature peptide-loaded dendritic cells by         intralymphatic and intranodal routes in metastatic melanoma         patients. Clin Cancer Res, 2006. 12 (24): p. 7380-8.     -   95. Guo, J., et al., Intratumorml injection of dendritic cells         in combination with local hyperthermia induces systemic antiumor         effect in patients with advanced melanoma. Int J Cancer, 2001.         120 (11): p. 2418-25.     -   96. O'Rourke, M. G., et al., Dendritic all immunotherapy for         stage IV melanoma. Melanoma Res, 2007. 17 (5): p. 316-22.     -   97. Bercovici, N., et al., Analysis and characterization of         antitumor T-cell response after administration of dendritic         ceils loaded with allogeneic tumor lysate to metastatic melanoma         patients. J Immunother, 2008. 31 (1): p. 101-12.     -   98. Hersey, P., et al., Phase I/II study of treatment with         matured dendritic cells with or without low dose IL-2 in         patienis with disseminated melanoma. Cancer Immunol         Immunother, 2008. 57 (7): p. 1039-51.     -   99. von Euw, E. M., et al., A phase I clinical study of         vaccination of melanoma patients with dendritic cells loaded         with allogeneic apoptotic/necrotic melanoma cells. Analysis of         toxicity and immune response to the vaccine and of IL-10-1082         promoter genotype as predictor of disease progression. J Transl         Med, 2008. 6: p. 6.     -   100. Carrasco, J., et al., Vaccination of a melanoma patient         with mature dendritic cells pulsed with MAGE-3 peptides triggers         the activity of nonvaccine anti-tumor cells. J Immunol, 2008.         180 (5): p. 3585-93.     -   101. Redman, B. G., et al., Phase Ib trial assessing autologous,         tumor-pulsed dendritic cells as a vaccine administered with or         without IL-2 in patients with metastatic melanoma. J         Immunother, 2008. 31 (6): p. 591-8.     -   102. Daud, A. I., et al., Phenotypic and functional analysis of         dendritic cells and clinical outcome in patients with high-risk         melanoma treated with adjuvant granulocyte macrophage         colony-stimulating factor. J Clin Oncol, 2008. 26 (19): p.         3235-41.     -   103. Engell-Noerregaard, L., et al., Review of clinical studies         on dendritic cell-based vaccination of patients with malignant         melanoma: assessment of correlation between clinical response         and vaccine parameters. Cancer Immunol Immunother, 2009 58         (1): p. 1-14.     -   104. Nakai, N., et al., Immunohistological analysis of         peptide-induced delayed-type hypersensitivity in advanced         melanoma patients treated with melanoma antigen-pulsed mature         monocyte-derived dendritic cell vaccination. J Dermatol         Sci, 2009. 53 (1): p. 40-7.     -   105. Dillman, R. O., et al., Phase II trial of dendritic cells         loaded with antigens from self-renewing, proliferating         autologous tumor cells at patient-specific antitumor vaccines in         patients with metastatic melanoma: final report. Cancer Biother         Radiopharm, 2009. 24 (3): p. 311-9.     -   106. Chang, J. W., et al., Immunotherapy with dendritic cells         pulsed by autologous dactinomycin-induced melanoma apoptolic         bodies for patients with malignant melanoma. Melanoma Res, 2009.         19 (5): p. 309-15.     -   107. Trepiakas, R., et al., Vaccination with autologous         dendritic cells pulsed with multiple tumor antigens for         treatment of patients with malignant melanoma: results from a         phase I/II trial. Cytotherapy, 2010. 12 (6): p. 721-34.     -   108. Jacobs, J. F., et al., Dendritic cell vaccination in         combination with anti-CD25 monoclonal antibody treatment: a         phase I/II study in metastatic melanoma patients. Clin Cancer         Res, 2010. 16 (20): p. 5067-78.     -   109. Ribas, A., et al., Multicenter phase II study of matured         dendritic cells pulsed with melanoma cell line lysates in         patients with advanced melanoma. J Transl Med, 2010. 8: p. 89.     -   110. Ridolfi, L., et al., Unexpected high response rate to         traditional therapy after dendritic cell-based vaccine in         advanced melanoma: update of clinical outcome and subgroup         analysis. Clin Dev Immunol, 2010. 2010: p. 504979.     -   111. Comfort, A. N., et al., Resistance to the proapoptotic         effects of interferon-gamma on melanoma cells used in         patient-specific dendritic cell immunotherapy is associated with         improved overall survival. Cancer Immunol Immunother, 2011. 60         (1): p. 123-31.     -   112. Lesterhuis, W. J., et al., Wild-type and modified gp100         peptide-pulsed dendritic cell vaccination of advanced melanoma         patients can lead to long-term clinical responses independent of         the peptide used. Cancer Immunol Immunother, 2011. 60 (2): p.         249-60.     -   113. Bjoern, J., et al., Changes in peripheral blood level of         regulatory T cells in patients with malignant melanoma during         treatment with dendritic cell vaccination and low-dose IL-2.         Scand J Immunol, 2011. 73 (3): p. 222-33.     -   114. Steele, J. C., et al., Phase I/II trial of a dendritic cell         vaccine transfected with DNA encoding melan A and gp100 for         patients with metastatic melanoma. Gene Ther. 2011. 18 (6): p.         584-93.     -   115. Kim, D. S., et al., Immunotherapy of malignant melanoma         with tumor lysate-pulsed autologous monocyte-derived dendritic         cells. Yonsei Med J, 2011. 52 (6): p. 990-8.     -   116. Ellebaek, E., et al., Metastatic melanoma patients treated         with dendritic cell vaccination, Interleukin-2 and metronomic         cyclophosphamide: results from a phase II trial. Cancer Immunol         Immunother, 2012. 61 (10): p. 1791-804.     -   117. Dillman, R. O., et al., Tumor stem cell antigens as         consolidative active specific immunotherapy: a randomized phase         II trial of dendritic cells versus tumor cells in patients with         metastatic melanoma. J Immunother, 2012. 35 (8): p. 641-9.     -   118. Dannull, J., et al., Melanoma immunotherapy using mature         DCs expressing the constitutive proteasome. J Clin Invest, 2013.         123 (7): p. 3135-45.     -   119. Finkelstein, S. E., et al., Combination of extemal beam         radiotherapy (EBRT) with intratumoral injection of dendritic         cells as neo-adjuvant treatment of high-risk soft tissue sarcoma         patients. Int J Radiat Oncol Biel Phys, 2012. 82 (2): p, 924-32.     -   120. Stift, A., et al., Dendritic cell vaccination in medullary         thyroid carcinoma. Clin Cancer Res, 2004. 10 (9): p. 2944-53.     -   121. Kuwabara, K., et al., Results of a phase I clinical study         using dendritic cell vaccinations for thyroid cancer.         Thyroid, 2007. 17 (1): p. 53-8.     -   122. Bachleitner-Hofmann, T., et al., Pilot trial of autologous         dendritic cells loaded with tumor lysate(s) from allogeneic         tumor cell lines in patients with metastatic medullary thyroid         carcinoma. Oncol Rep, 2009. 21 (6): p. 1585-92.     -   123. Yu, J. S., et al., Vaccination of malignant glioma patients         with peptide-pulsed dendritic cells elicits systemic         cytotoxicity and intracranial T-cell infiltration. Cancer         Res, 2001. 61 (3): p. 842-7.     -   124. Yamanaka, R., et al., Vaccination of recurrent glioma         patients with tumour lysate-pulsed dendritic cells elicits         immune responses: results of a clinical phase I/II trial. Br J         Cancer, 2003. 89 (7): p. 1172-9.     -   125. Yu, J. S., et al., Vaccination with tumor lysate-pulsed         dendritic cells elicits antigen-specific, cytotoxic T-cells in         patients with malignant glioma. Cancer Res, 2004. 64 (14): p.         4973-9.     -   126. Yamanaka, R., et al., Tumor lysate and IL-18 loaded         dendritic cells elicits Th1 response, tumor-specific CD8+         cytotoxic T cells in patients with malignant glioma. J         Neurooncol, 2005. 72 (2): p. 107-13.     -   127. Yamanaka, R., et al., Clinical evaluation of dendritic cell         vaccination for patients with recurrent glioma: results of a         clinical phase I/II trial. Clin Cancer Res, 2005. 11 (11): p.         4160-7.     -   128. Liau, L. M., et al., Dendritic cell vaccination in         glioblastoma patients induces systemic and intracranial T-cell         responses modulated by the local central nervous system tumor         microenvironment. Clin Cancer Res, 2005. 11 (15): p. 5515-25.     -   129. Walker, D. G., et al., Results of phase I dendritic cell         vaccine trial for malignant astrocytoma: potential interaction         with adjuvant chemotherapy. J Clin Neurosci, 2008. 15 (2): p.         114-21.     -   130. Leplina, O. Y., et al., Use of interferon-alpha-induced         dendritic cells in the therapy of patients with malignant brain         gliomas. Bull Exp Biol Med, 2007. 143 (4): p. 528-34.     -   131. De Vleeschouwer, S., Postoperative adjuvant dendritic         cell-based immunotherapy in patients with relapsed glioblastoma         multiforme. Clin Cancer Res, 2008. 14 (10): p. 3098-104.     -   132. Ardon, H., et al., Adjuvent dendritic cell-based tumour         vaccination for children with malignant tumours. Pediatr Blood         Cancer, 2010. 54 (4): p. 519-25.     -   133. Prins, R. M., et al., Gene expression profile correlates         with T-cell infiltration and relative survival in glioblastoma         patients vaccinated with dendritic cell immunotherapy. Clin         Cancer Res, 2011. 17 (6): p. 1603-15.     -   134. Okada, H., et al., Induction of CD8+ T-cell responses         against novel glioma-associated antigen peptides and clinical         activity by vaccinations with {alpha}-type 1 polarized dendritic         cells and polyinosinic-polycytidylic acid stabilized by lysine         and carboxymethylcellulose in patients with recurrent malignant         glioma. J Clin Oncol, 2011. 29 (3): p. 330-6.     -   135. Fadul, C. E., et al., Immune response in patients with         newly diagnosed glioblastoma multiforme treated with intranodal         autologous tumor lysate-dendritic cell vaccination after         radiation chemotherapy. J Immunother, 2011. 34 (4): p. 382-9.     -   136. Chang, C. N., et al., A phase I/II clinical trial         investigating the adverse and therapeutic effects of a         postoperative autologous dendritic cell tumor vaccine in         patients with malignant glioma. J Clin Neurosci, 2011. 18         (8): p. 1048-54.     -   137. Cho, D. Y., et al., Adjuvant immunotherapy with whole-cell         lysate dendritic cells vaccine for glioblastoma multiforme: a         phase II clinical trial. World Neurosurg, 2012. 77 (5-6): p.         736-44.     -   138. Iwami, K., et al., Peptide-pulsed dendritic cell         vaccination targeting interleukin-13 receptor alpha2 chain in         recurrent malignant glioma patients with HLA-A*24/A*02 allele.         Cytotherapy, 2012. 14 (6): p. 733-42.     -   139. Fong, B., et al., Monitoring of regulatory T cell         frequencies and expression of CTLA-4 on T cells, before and         after DC vaccination, can predict survival in GBM patients. PLoS         One, 2012. 7 (4): p. e32614.     -   140. De Vleeschouwer, S., et al. Stratification according to         HGG-IMMUNO RPA model predicts outcome in a large group of         patients with relapsed malignant glioma treated by adjuvant         postoperative dendritic cell vaccination. Cancer Immunol         Immunother, 2012. 61 (11): p. 2105-12.     -   141. Phuphanich, S., et al., Phase I trial of a         multi-epitope-pulsed dendritic cell vaccine for patients with         newly diagnosed glioblastoma. Cancer Immunol Immunother, 2013.         62 (1): p, 125-35.     -   142. Akiyama, Y., et al., alpha-type-1 polarized dendritic         cell-based vaccination in recurrent high-grade glioma: a phase I         clinical trial. BMC Cancer, 2012. 12: p. 623.     -   143. Prins, R. M., et al., Comparison of glioma-associated         antigen peptide-loaded versus autologous tumor lysate-loaded         dendritic cell vaccination in malignant glioma patients. J         Immunother, 2013. 36 (2): p. 152-7.     -   144. Shah, A. H., et al., Dendritic cell vaccine for recurrent         high-grade gliomas in pediatric and adult subjects: clinical         trial protocol. Neurosurgery, 2013. 73 (5): p. 863-7.     -   145. Reichardt, V. L., et al., Idiotype vaccination using         dendritic cells after autologous peripheral blood stem cell         transplantation for multiple myeloma—a feasibility study.         Blood, 1999. 93 (7): p. 2411-9.     -   146. Lim, S. H. and R. Bailey-Wood. Idiotypic protein-pulsed         dendritic cell vaccination in multiple myeloma. Int J         Cancer, 1999. 83 (2): p. 215-22.     -   147. Motta, M. R., et al., Generation of dendritic cells from         CD14+ monocytes positively selected by immunomagnetic adsorption         for multiple myeloma patients enrolled in a clinical trial of         anti-idiotype vaccination. Br J Haematol, 2003. 121 (2): p.         240-50.     -   148. Reichardt, V. L., et al., Idiotype vaccination of multiple         myeloma patients using monocyte-derived dendritic cells.         Haematologica, 2003. 88 (10): p. 1139-49.     -   149. Guardino, A. E., et al., Production of myeloid dendritic         cells (DC) pulsed with tumor-specific idiotype protein for         vaccination of patients with multiple myeloma.         Cytotherapy, 2006. 8 (3): p. 277-89.     -   150. Lacy, M. Q., et al., Idiotype-pulsed antigen-presenting         cells following autologous transplantation for multiple myeloma         may be associated with prolonged survival. Am J Hematol, 2009.         84 (12): p. 799-802.     -   151. Yi, Q., et al., Optimizing dendritic cell-based         immunotherapy in multiple myeloma: intranodal injections of         idiotype-pulsed CD40 ligand-matured vaccines led to induction of         type-1 and cytotoxic T-cell immune responses in patients. Br J         Haematol, 2010. 150 (5): p. 554-64.     -   152. Rollig, C., et al., Induction of cellular immune responses         in patients with stage-I multiple myeloma after vaccination with         autologous idiotype-pulsed dendritic cells. J Immunother, 2011.         34 (1): p 100-6.     -   153. Zahradova, L., et al., Efficacy and safety of         Id-protein-loaded dendritic cell vaccine in patients with         multiple myeloma—phase II study results. Neoplasma, 2012. 59         (4): p. 440-9.     -   154. Timmerman, J. M., et al., Idiotype-pulsed dendritic cell         vaccination for B-cell lymphoma: clinical and immune responses         in 35 patients. Blood, 2002. 99 (5): p. 1517-26.     -   155. Maier, T., et al., Vaccination of patients with cutaneous         T-cell lymphoma using intranodal injection of autologous         tumor-lysate-pulsed dendritic cells. Blood, 2003. 102 (7): p.         2338-44.     -   156. Di Nicola, M., et al., Vaccination with autologous         tumor-loaded dendritic cells induces clinical and immunologic         responses in indolent B-cell lymphoma patients with relapsed and         measurable disease: a pilot study. Blood, 2009. 113 (1): p.         18-27.     -   157. Hus, I., et al., Allogeneic dendritic cells pulsed with         tumor lysates or apoptotic bodies as immunotherapy for patients         with early-stage B-cell chronic lymphocytic leukemia.         Leukemia, 2005. 19 (9): p. 1621-7.     -   158. Li, L., et al., Immunotherapy for patients with acute         myeloid leukemia using autologous dendritic cells generated from         leukemic blasts. Int J Oncol, 2006. 28 (4): p. 855-61.     -   159. Roddie, H., et al., Phase I/II study if vaccination with         dendritic-like leukaemia cells for the immunotherapy of acute         myeloid leukaemia. Br J Haematol, 2006. 133 (2): p. 152-7.     -   160. Litzow, M. R., et al., Testing the safety of clinical-grade         mature autologous myeloid DC in a phase I clinical immunotherapy         trial of CML. Cytotherapy, 2006. 8 (3): p. 290-8.     -   161. Westermann, J., et al., Vaccination with autologous         non-irradiated dendritic cells in patients with bcr/abl+ chronic         myeloid leukaemia. Br J Haematol, 2007. 137 (4): p. 297-306.     -   162. Hus, I., et al., Vaccination of B-CLL patients with         autologous dendritic cells can change the frequency of leukemia         antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+         regulatory T cells toward an antileukemia response.         Leukemia, 2008. 22 (5): p. 1007-17.     -   163. Palma, M., et al., Development of a dendritic cell-based         vaccine for chronic lymphocytic leukemia. Cancer Immunol         Immunother, 2008. 57 (11): p. 1705-10.     -   164. Van Tendeloo, V. F., et al., Induction of complete and         molecular remissions in acute myeloid leukemia by Wilms' tumor I         antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci         USA, 2010. 107 (31): p. 13824-9.     -   165. Iwashita, Y., et al., A phase I study of autologous         dendritic cell-based immunotherapy for patients with         umresectable primary liver cancer. Cancer Immunol         Immunother, 2003. 52 (3): p. 155-61.     -   166. Lee, W. C., et al., Vaccination of advanced hepatocellular         carcinoma patients with tumor lysate-pulsed dendritic cells: a         clinical trial. J Immunother, 2005. 28 (5): p. 496-504.     -   167. Butterfield, L. H., et al., A phase I/II trial testing         immunization of hepatocellular carcinoma patients with dendritic         cells pulsed with four alpha-fetoprotein peptides. Clin Cancer         Res, 2006. 12 (9): p. 2817-25.     -   168. Palmer, D. H., et al., A phase II study of adoptive         immunotherapy using dendritic cells pulsed with tumor lysate in         patients with hepatocellular carcinoma. Hepatology, 2009. 49         (1): p. 124-32.     -   169. El Ansary, M., et al., Immunotherapy by autologous         dendritic cell vaccine in patients with advanced HCC. J Cancer         Res Clin Oncol, 2013. 139 (1): p. 39-48.     -   170. Tada, F., et al., Phase I/II study of immunotherapy using         tumor antigen-pulsed dendritic cells in patients with         hepatocellular carcinoma. Int J Oncol, 2012. 41 (5): p. 1601-9.     -   171. Ueda, Y., et al., Dendritic cell-based immunotherapy of         cancer with carcinoembryonic antigen-derived, HLA-A24-restricted         CTL epitope: Clinical outcomes of 18 patients with metastatic         gastrointestinal or lung adenocarcinomas. Int J Oncol, 2004. 24         (4): p. 909-17.     -   172. Hirschowitz, E. A., et al., Autologous dendritic cell         vaccines for non-small-cell lung cancer. J Clin Oncol, 2004. 22         (14): p. 2808-15.     -   173. Chang, G. C., et al., A pilot clinical trial of vaccination         with dendritic cells pulsed with autologous tumor cells derived         front malignant pleural effusion in patients with late-stage         lung carcinoma. Cancer, 2005. 103 (4): p. 763-71.     -   174. Yannelli, J. R., et al., The large scale generation of         dendritic cells for the immunization of patients with non-small         cell lung cancer (NSCLC). Lung Cancer, 2005. 47 (3): p. 337-50.     -   175. Ishikawa, A., et al., A phase I study of         alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in         patients with advanced and recurrent non-small cell lung cancer.         Clin Cancer Res, 2005. 11 (5): p. 1910-7.     -   176. Antonia, S. J., et al., Combination of p53 cancer vaccine         with chemotherapy in patients with extensive stage small cell         lung cancer. Clin Cancer Res, 2006. 12 (3 Pt 1): p. 878-87.     -   177. Perrot, I., et al., Dendritic cells infiltrating human         non-small cell lung cancer are blocked at immature stage. J         Immunol, 2007. 178 (5): p. 2763-9.     -   178. Hirschowitz, E. A., et al., Immunization of NSCLC patients         with antigen-pulsed immature autologous dendritic cells. Lung         Cancer, 2007. 57 (3): p. 365-72.     -   179. Baratelli, F., et al., Pre-clinical characterization of CMP         grade CCL21-gene modified dendritic cells for application in a         phase I trial in non-small cell lung cancer. J Transl Med, 2008.         6: p. 38.     -   180. Hegmans, J. P., et al., Consolidative dendritic cell-based         immunotherapy elicits cytotoxicity against malignant         mesothelioma. Am J Respir Crit Care Med, 2010. 181 (12): p.         1383-90.     -   181. Um, S. J., et al., Phase I study of autologous dendritic         cell tumor vaccine in patients with non-small cell lung cancer.         Lung Cancer, 2010. 70 (2): p. 188-94.     -   182. Chiappori, A. A., et al., INGN-225: a dendritic cell-based         p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed         association between immune response and enhanced chemotherapy         effect. Expert Opin Biol Ther, 2010. 10 (6): p. 983-91.     -   183. Perroud, M. W., Jr., et al., Mature autologous dendritic         cell vaccines in advanced non-small cell lung cancer: a phase I         pilot study. J Exp Clin Cancer Res, 2011. 30: p. 65.     -   184. Skachkova, O. V., et al., Immunological markers of         anti-tumor dendritic cells vaccine efficiency in patients with         non-small cell lung cancer. Exp Oncol, 2013. 35 (2): p. 109-13.     -   185. Hernando, J. J., et al., Vaccination with autologous tumur         antigen-pulsed dendritic cells in advanced gynaecological         malignancies: clinical and immunological evaluation of a phate I         trial. Cancer Immunol Immunother, 2002. 51 (1): p. 45-52.     -   186. Rahma, O. E., et al., A gynecologic oncology group phase II         trial of two p53 peptide vaccine approaches: subcutaneous         injection and intravenous pulsed dendritic cells in high         recurrence risk ovarian cancer patients. Cancer Immunol         Immunother, 2012. 61 (3): p. 373-84.     -   187. Chu, C. S., et al., Phase I/II randomized trial of         dendritic cell vaccination with or without cyclophosphamide for         consolidation therapy of advanced ovarian cancer in first or         second remission. Cancer Immunol Immunother, 2012. 61 (5): p.         629-41.     -   188. Kandalaft, L. E., et al., A Phase I vaccine trial using         dendritic cells pulsed with autologous oxidized lysate for         recurrent ovarian cancer. J Transl Med, 2013. 11: p. 149.     -   189. Lepisto, A. J., et al., A phase I/II study of a MUC1         peptide pulsed autologous dendritic cell vaccine as adjuvant         therapy in patients with resected pancreatic and biliary tumors.         Cancer Ther, 2008. 6 (B): p. 955-964.     -   190. Rong, Y., et al., A phase I pilot trial of         MUC1-peptide-pulsed dendritic cells in the treatment of advanced         pancreatic cancer. Clin Exp Med, 2012. 12 (3): p. 173-80.     -   191. Endo, H., et al., Phase I trial of preoperative         intratumoral injection of immature dendritic cells and OK-432         for resectable pancreatic cancer patients. J Hepatobiliary         Pancreat Sci, 2012. 19 (4): p. 465-75.     -   192. Tsujitani, S., et al., Infiltration of dendritic cells in         relation to tumor invasion and lymph node metastasis in human         gastric cancer. Cancer, 1990. 66 (9): p. 2012-6.     -   193. Tsujitani. S., et al., Postoperative adjuvant         immunochemotherapy and infiltration of dendritic cells for         patients with advanced gastric cancer. Anticancer Res, 1992. 12         (3): p. 645-8.     -   194. Kakeji, Y., et al., Prognostic significance of tumor-host         interaction in clinical gastric cancer: relationship between DNA         ploidy and dendritic cell infiltration. J Surg Oncol, 1993. 52         (4): p. 207-12.     -   195. Ishigami, S., et al., Prognostic value of HLA-DR expression         and dendritic cell infiltration in gastric cancer.         Oncology, 1998. 55 (1): p. 65-9.     -   196. Giannini, A., et al., Prognostic significance of accessory         cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res         Pract, 1991. 187 (4): p. 496-502.     -   197. Gallo, O., et al., Correlations between histopathological         and biological findings in nasopharyngeal carcinoma and its         prognostic significance. Laryngoscope, 1991. 101 (5): p. 487-93.     -   198. Furihata, M., et al., HLA-DR antigen- and S-100         protein-positive dendritic cells in esophageal squamous cell         carcinoma—their distribution in relation to prognosis. Virchows         Arch B Cell Pathol Incl Mol Pathol, 1992. 61 (6): p. 409-14.     -   199. Reichert, T. E., et al., The number of intratumorml         dendritic cells and zeta-chain expression in T cells as         prognostic end survival biomarkers in patients with oral         carcinoma. Cancer, 2001. 91 (11): p. 2136-47.     -   200. Timar, J., et al., Neoadjuvant immunotherapy of oral         squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and         tumor microenvironment: a multicenter phase II clinical trial. J         Clin Oncol, 2005. 23 (15): p. 3421-32.     -   201. Nakano, T., et al., Antitumor activity of Langerhans cells         in radiation therapy for cervical cancer and its modulation with         SPG administration. In Vivo, 1993. 7 (3): p. 257-63.     -   202. Lespagnard, L., et al., Tumor-infiltrating dendritic cells         in adenocarcinomas of the breast: a study of 143 neoplasms with         a correlation to usual prognostic factors and to clinical         outcome. Int J Cancer, 1999. 84 (3): p. 309-14.     -   203. Iwamoto, M., et al., Prognostic value of tumor-infiltrating         dendritic cells expressing CD83 in human breast carcinomas. Int         J Cancer, 2003. 104 (1): p. 92-7.     -   204. Coventry, B. J. and J. Morton. CD1a-positive         infiltrating-dendritic cell density and 5-year survival from         human breast cancer. Br J Cancer, 2003. 89 (3): p. 533-8.     -   205. Zhao, R., et al., [Study on the relationship between the         dendritic cell infiltration in cancer tissues and prognosis in         patients with lung cancer]. Zhongguo Fei Ai Za Zhi, 2002. 5         (2): p. 112-4.     -   206. Diederichsen, A. C., et al., Prognostic value of the         CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal         cancer and HLA-DR expression on tumour cells. Cancer Immunol         Immunother, 2003. 52 (7): p. 423-8.     -   207. Dadabayev, A. R., et al., Dendritic cells in colorectal         cancer correlate with other tumor-infiltrating immune cells.         Cancer Immunol Immunother, 2004. 53 (11): p. 978-86.     -   208. Sandel, M. H., et al., Prognostic value of         tumor-infiltrating dendritic cells in colorectal cancer: role of         maturation status and intratumoral localization. Clin Cancer         Res, 2005. 11 (7): p. 2576-82.     -   209. Yin, X.Y., et al., Prognostic significances of         tumor-infiltrating S-100 positive dendritic cells and         lymphocytes in patients with hepatocellular carcinoma.         Hepatogastroenterology, 2003. 50 (53): p. 1281-4.     -   210. Cai, X. Y., et al., Dendritic cell infiltration and         prognosis of human hepatocellular carcinoma. J Cancer Res Clin         Oncol, 2006. 132 (5): p. 293-301.     -   211. Nakakubo, Y., et al., Clinical significance of immune cell         infiltration within gallbladder cancer. Br J Cancer, 2003. 89         (9): p. 1736-42.     -   212. Furihata, M., et al., Prognostic significance of CD83         positive, mature dendritic cells in the gallbladder carcinoma.         Oncol Rep, 2005. 14 (2): p. 353-6.     -   213. Fukunaga, A., et al., CD8+ tumor-infiltrating lymphocytes         together with CD4+ tumor-infiltrating lymphocytes and dendritic         cells improve the prognosis of patients with pancreatic         adenocarcinoma. Pancreas, 2004. 28 (1): p. c26-31. 

1-18. (canceled)
 19. A method of enhancing an efficacy of an antibody administered to a patient, comprising the steps of: (a) administering an antibody capable of suppressing activity of a checkpoint protein selected from a group consisting of a LAG3, a Tim3, a 2B4, a A2aR, a ID02, a BTLA, a DR3, a GAL9, a HVEM, a ID01, a KIR, a LAIR, a LIGHT, a MARCO, a PS, a SLAM, a TIGIT, a VISTA, a VTCN1, a CD2, a CD20, a CD30, a CD33, a CD52, a CD70, a CD112, a CD160, and a CD226 molecule; (b) extracorporeally removing an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.
 20. The method of claim 19, wherein the antibody is selected from a group consisting of IMP321, ibritumomab tiuxetan, ofatumumab, rituximab, obinutuzumab, tositumomab, brentuximab vedotin, gemtuzumab ozogamicin, and alemtuzumab.
 21. The method of claim 19, wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.
 22. The method of claim 21, wherein step (b) is performed using an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.
 23. The method of claim 22, wherein the immobilized TNF-alpha molecule is a trimer.
 24. The method of claim 19, further comprising after step (b) administering an antibody capable of suppressing activity of a checkpoint protein selected from a group consisting of a LAG3, a Tim3, a 2B4, a A2aR, a ID02, a BTLA, a DR3, a GAL9, a HVEM, a ID01, a KIR, a LAIR, a LIGHT, a MARCO, a PS, a SLAM, a TIGIT, a VISTA, a VTCN1, a CD2, a CD20, a CD30, a CD33, a CD52, a CD70, a CD112, a CD160, and a CD226 molecule one or more additional times to the patient.
 25. The method of claim 19, further comprising after step (b) extracorporeally removing one or more additional times an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.
 26. The method of claim 19, wherein step (a) is performed before step (b).
 27. The method of claim 19, wherein step (b) is performed before step (a).
 28. An extracorporeal system for enhancing an efficacy of an antibody administered to a patient, comprising: a column configured to deplete a portion of an immunological blocking factor that reduces the efficacy of the antibody from blood or a blood component of the patient; wherein the antibody is capable of suppressing activity of a checkpoint protein selected from the group consisting of a LAG3, a Tim3, a 2B4, a A2aR, a ID02, a BTLA, a DR3, a GAL9, a HVEM, a ID01, a KIR, a LAIR, a LIGHT, a MARCO, a PS, a SLAM, a TIGIT, a VISTA, a VTCN1, a CD2, a CD20, a CD30, a CD33, a CD52, a CD70, a CD112, a CD160, and a CD226 molecule.
 29. The system of claim 28, wherein the antibody is selected from a group consisting of IMP321, ibritumomab tiuxetan, ofatumumab, rituximab, obinutuzumab, tositumomab, brentuximab vedotin, gemtuzumab ozogamicin, and alemtuzumab.
 30. The system of claim 28, wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.
 31. The system of claim 30, wherein the column comprises an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.
 32. The system of claim 31, wherein the affinity capture substrate is a trimer. 